预约演示
更新于：2026-01-29
ADX-038
更新于：2026-01-29
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床申请批准 |
特殊审评- |
登录后查看时间轴
结构/序列
使用我们的RNA技术数据为新药研发加速。
登录
或
关联
3
项与 ADX-038 相关的临床试验NCT06990269
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT06989359
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
NCT05876312
A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Participants Followed by a Phase 2a Open Label Study in Participants With PNH and Residual Anemia to Evaluate the Safety, Tolerability, PK and PD of ADX-038
100 项与 ADX-038 相关的临床结果
登录后查看更多信息
100 项与 ADX-038 相关的转化医学
登录后查看更多信息
100 项与 ADX-038 相关的专利（医药）
登录后查看更多信息
42
项与 ADX-038 相关的文献（医药）2026-01-01JOURNAL OF CONTROLLED RELEASE
Hypoxia-responsive modules via tunable hydrophobicity reversal enhance renal-targeted release of CD36-interfering nanoparticles to ameliorate acute kidney injury
Article
作者: Liao, Xiaohui ; Wei, Li ; Liu, Chen ; Chen, Yaxi ; Ruan, Xiong Z ; Su, Yu ; Zhao, Lulu ; Wen, Haobo ; Hu, Ke ; Zhao, Yunfei ; Zou, Gang ; Wang, Ping ; Zhang, Tao
RNA interference (RNAi) has led to multiple FDA-approved therapeutics and boasts a robust clinical pipeline. However, its transformation for kidney disease remains hindered by the absence of effective delivery vehicles, which are constrained by low delivery efficiency and non-target organ release. Herein, six novel modules of 2-(2-nitro-1H-imidazol-1-yl)ethanamine (IEN) with different carbon-chain linkers were designed and synthesized, then subsequently grafted onto chitosan (CS-Linker-IEN) to enable efficient delivery of RNAi in renal tissues. The CS-Linker-IEN self-assembles with siRNA into spherical nanoparticles (CS-Linker-IEN/siRNA) primarily through electrostatic, hydrogen-bond, and tunable hydrophobic interactions. This assembly enables the screening of an optimal size driven by tunable hydrophobicity and achieves efficient delivery to renal proximal tubule epithelial cells, with the smallest-sized CS-Hex-IEN/siRNA nanoparticles exhibiting the highest renal accumulation. Under hypoxic conditions characteristic of specific kidney diseases, the IEN moiety undergoes a structural transformation into 2-(2-amino-1H-imidazol-1-yl)ethanamine (AIE). This transformation reverses the hydrophobic-hydrophilic interactions, thereby enabling kidney-specific siRNA release. In a murine model of IRI-induced acute kidney injury (AKI), CS-Linker-IEN demonstrated targeted release of siCD36 to renal tubular epithelial cells, effectively mediating CD36 interference. This intervention conferred renoprotective effects through restoration of lipid metabolism, attenuation of oxidative stress, and suppression of the NF-κB signaling pathway. Given a plethora of kidney diseases that could benefit from RNAi, it is anticipated that this finding will expand the preclinical landscape of renal therapeutics.
2025-06-01JOURNAL OF CONTROLLED RELEASE
Hybrid micellar preparations for co-delivery of PARP-1 siRNA and quercetin for cataract treatment
Article
作者: He, Yao ; Zou, Zhilin ; Yalamarty, Satya Siva Kishan ; Li, Xiang ; Zhang, Jing ; Torchilin, Vladimir P ; Filipczak, Nina
Cataract remains a major cause of ocular blindness. Cyclic Arg-Gly-Asp-d-Phe-Lys (RGD) peptide was introduced to the surface of self-assembled hybrid micelles for the co-delivery of poly (ADP-ribose) polymerase 1 (PARP-1) small-interfering RNA (siRNA) and quercetin (Q/siP-c-M). Q/siP-c-M exhibited uniform particle size distribution, good dispersibility, high encapsulation efficiency, and strong stability for siRNA and quercetin. Q/siP-c-M significantly improved the transcorneal co-delivery of siRNA and quercetin to the deeper cornea and led to greater drug accumulation. In addition, Q/siP-c-M significantly increased the activity of catalase and the content of adenosine triphosphate (ATP), reduced the expression of PARP-1 protein, and effectively prevented lipid peroxidation in the lens. Among selenite-induced cataract rats, the Q/siP-c-M-treated rats produced higher levels of ATP and catalase, as well as lower levels of malondialdehyde and PARP-1 protein expression compared with those in the model group. Administration of quercetin further resulted in a decrease in neutrophil extracellular trap formation and downregulation of gene expression of related proteins and pro-inflammatory cytokines. These observations indicated that quercetin has the potential to serve as a therapeutic for alleviating an excessive inflammatory reaction characterized by an overabundance of neutrophil extracellular traps in the eyes. Therefore, this study highlights the potential of Q/siP-c-M against cataract development through the regulation of the immune response by regulating inflammatory conditions. Furthermore, Q/siP-c-M may offer benefits in terms of apoptosis attenuation for lens epithelial cells.
2024-09-01BIOMEDICINE & PHARMACOTHERAPY
Carboxylated mesoporous silica nanoparticle-nucleic acid chimera conjugate-assisted delivery of siRNA and doxorubicin effectively treat drug-resistant bladder cancer.
Article
作者: Shang, Zhenhua ; Chen, Wen ; Wang, Xu ; Wang, Qi ; Ou, Tongwen ; Liu, Biao ; Yang, Jintao ; Yan, Hao ; Li, Guangping
Chemotherapy is the main treatment for bladder cancer, but drug resistance and side effects limit its application and therapeutic effect. Herein, we constructed doxorubicin (DOX)/COOH-mesoporous silica nanoparticle/polyethylenimine (PEI)/nucleic acid chimeras (DOX/MSN/Chimeras) to reduce the toxicity of chemotherapy drugs and the resistance of bladder cancer cells. Transmission electron microscopy showed that PEI was coated on the DOX/MSN/BSA nanoparticles with a diameter of about 150 nm. DOX/MSN/PEI could control DOX release for over 48 h, and the sudden release rate was significantly lower than DOX/MSN. Immunohistochemical results showed that DOX/MSN/Chimera specifically bound to bladder cancer cells, and markedly inhibited PI3K expression and proliferation of DOX-resistant bladder cancer cells. DOX/MSN/Chimera promoted the apoptosis of drug-resistant bladder cancer cells, which was superior to DOX/MSN/Aptamer or DOX/MSN. We further carried out animal experiments and found that DOX/MSN/Chimera could reduce the volume of transplanted tumors in vivo. Compared with DOX/MSN/Aptamer group, the proliferation rate was significantly decreased and the proportion of apoptotic cells was highly increased. Through the histological observation of kidneys and lungs, we believed that DOX/MSN/Chimera can effectively reduce the damage of chemotherapy drugs to normal tissues. In conclusion, we constructed a COOH-MSN/nucleic acid chimera conjugate for the targeted delivery of siRNA and anti-cancer drugs. Our study provides a new method for personalized and targeted treatment of drug-resistant bladder cancer.
100 项与 ADX-038 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 年龄相关性黄斑变性 | 临床2期 | 美国 | 2025-11-10 | |
| 年龄相关性黄斑变性 | 临床2期 | 澳大利亚 | 2025-11-10 | |
| 年龄相关性黄斑变性 | 临床2期 | 加拿大 | 2025-11-10 | |
| 地图样萎缩 | 临床2期 | 美国 | 2025-11-10 | |
| 地图样萎缩 | 临床2期 | 澳大利亚 | 2025-11-10 | |
| 地图样萎缩 | 临床2期 | 加拿大 | 2025-11-10 | |
| 补体因子H缺乏症 | 临床2期 | 美国 | 2025-08-28 | |
| 补体因子H缺乏症 | 临床2期 | 澳大利亚 | 2025-08-28 | |
| 补体因子H缺乏症 | 临床2期 | 中国香港 | 2025-08-28 | |
| 补体因子H缺乏症 | 临床2期 | 韩国 | 2025-08-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 41 | 鹹衊齋簾遞遞鬱淵憲選(鏇鬱遞製鏇鏇窪簾壓顧) = The most common AE was upper respiratory tract infection, similar to placebo. There were no encapsulated bacterial infections nor clinically relevant changes in clinical lab tests, PE or vital signs. 膚膚顧鹹製廠齋窪選衊 (鏇範壓蓋築積鏇襯膚鏇 ) | 积极 | 2025-11-07 | |||
placebo | |||||||
临床1期 | 15 | 觸築襯蓋淵鹽襯繭築夢(艱膚觸鹽憲繭壓簾積鬱) = Most common treatment-related AEs: fatigue (47%), fever/chills (33%), allergic (33%), constipation (33%), nausea/vomiting (20%), all g1-2. 1 pt had g3 anemia and 2 pts had g2 thrombocytopenia, all shortly after CALAA-01 infusions with rapid recovery. 1 pt had possibly-related sinus bradycardia (g2) 選鬱製選積膚製獵鹽構 (範齋齋鑰鬱構鑰壓膚獵 ) 更多 | - | 2010-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用